Daniel H. Ahn, DO

Daniel H. Ahn, DO, discusses the evolution of first-line treatments in advanced hepatocellular carcinoma.

Daniel H. Ahn, DO, discusses the importance of drug toxicity when selecting between first-line immune checkpoint inhibitor–based regimens in hepatocellular carcinoma.

Daniel H. Ahn, DO, discusses the increased understanding of cholangiocarcinoma.

Daniel H. Ahn, DO, shares how to navigate among the therapeutic options available for patients with advanced, unresectable hepatocellular carcinoma.

Daniel H. Ahn, DO, discusses considerations for treatment with atezolizumab and bevacizumab in patients with hepatocellular carcinoma.

Daniel H. Ahn, DO, discusses the utility of atezolizumab in combination with bevacizumab in hepatocellular carcinoma.

Daniel H. Ahn, DO, discusses the growing role of circulating tumor DNA in colorectal cancer.

Daniel H. Ahn, DO, discusses the role of checkpoint inhibitor therapy in patients with microsatellite instability–high colorectal cancer who harbor an NTRK fusion.

Daniel H. Ahn, DO, discusses the identification of NTRK alterations in colorectal cancer.

Daniel H. Ahn, DO, discusses the significance of the phase 3 KEYNOTE-177 trial in patients with microsatellite instability–high metastatic colorectal cancer.

Daniel H. Ahn, DO, discusses the evolution of targetable alterations in colorectal cancer.

Daniel H. Ahn, DO, an oncologist, internist, and assistant professor of medicine at Mayo Clinic, discusses current limitations of targeted therapy in the colorectal cancer.

Daniel H. Ahn, DO, discusses ​updated findings from the ​phase 3 KEYNOTE-177 trial in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer.

Daniel H. Ahn, DO, discusses advancing actionable alterations in colorectal cancer.

Daniel H. Ahn, DO, discusses left- versus right-sided tumors in colorectal cancer.

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses biomarker-driven strategies in gastric and gastroesophageal junction (GEJ) cancers.

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses targeted therapies in gastric/esophageal cancers.

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses the role of immunotherapy in treating patients with gastric/gastroesophageal cancers.

Daniel H. Ahn, DO, internist, Mayo Clinic, discusses advances in neoadjuvant therapies for patients with gastric cancer during the 2017 OncLive State of the Science Summit on Gastrointestinal Malignancies.

Daniel H. Ahn, DO, internist, Mayo Clinic, discusses the identification of novel biomarkers in gastric cancer during the 2017 State of the Science Summit on Gastrointestinal Malignancies.